Latest Sustainability In It News

Service Stream Limited has locked in a significant $440 million contract with NBN Co to continue upgrading Australia’s fibre network, extending its role in the national infrastructure program.

Ventia has landed a major $800 million contract to upgrade 175,000 premises from Fibre to the Node to Fibre to the Premises across Australia, reinforcing its role in the nation’s digital infrastructure.

Norwood Systems has successfully delivered a crucial software milestone under a major telecom contract, while also reporting strong customer receipts that bolster its cash position.

North Stawell Minerals has launched a $3.6 million equity raising, anchored by a cornerstone investor, to fund exploration at key Victorian gold projects and sustain operational momentum through 2025.

Etherstack has landed a $1 million contract to supply digital radio network equipment to the world’s largest iron ore producer in Western Australia, reinforcing its growth in recurring revenues. The company also reports record cash receipts in the first half of 2025, signaling strong momentum.

Austin Engineering has raised its FY25 revenue guidance to $370 million, driven by strong growth in the Americas, but has lowered its EBIT forecast due to operational challenges in Chile.

GQG Partners has reported a steady rise in funds under management, reaching US$168.5 billion by the end of May 2025, supported by robust net inflows across key equity strategies.

Zip Co Limited has raised its FY25 cash EBTDA guidance to at least $160 million, driven by robust transaction growth in the US market exceeding 40% year-on-year in May 2025. The company also continues its share buy-back program amid steady credit performance.

Perseus Mining outlines a robust five-year gold production plan targeting up to 2.7 million ounces with stable costs and strong cash margins, backed by major projects in Africa.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Finbar Group has fast-tracked Ronald Chan’s appointment as CEO, aiming to leverage his deep company experience to strengthen its development pipeline and growth strategy.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.